+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

A Competitive Analysis of the Global Acute Coronary Syndrome (ACS) Therapeutics Market

  • ID: 3244520
  • Report
  • Region: Global
  • 69 Pages
  • Frost & Sullivan
1 of 4
Launch of Promising Late-stage Anti-hypertensive Drugs to Drive Growth of Branded ACS Therapeutics

FEATURED COMPANIES

  • Amgen
  • Bayer
  • Bristol Myers Squibb
  • Eli Lilly and Co.
  • GlaxoSmithKline
  • Merck & Co.
  • MORE
This research service offers an assessment for marketed and pipeline products for the global ACS therapeutics market. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology.

The marketed and pipeline products are broadly segmented into anti-platelet therapeutics, anti-hypertensives and cholesterol lowering drugs, anti-thrombins, and others. Other upcoming therapies include anti-inflammatories. The forecast period is 2015–2025.

Among the various classes of ACS therapeutics, anti-hypertensives and cholesterol lowering drugs are currently dominating the ACS therapeutics market with an influx of new drugs targeting novel pathways. The key drug targets include the proprotein convertase subtilisin/kexin type 9 (PCSK9) and cholesteryl ester transfer protein (CETP).

GSK has so far recruited patients for this trials to evaluate the safety of the drug in reducing the risk of cardiovascular events such as death, heart attack, or near heart attack that require urgent treatment. The enzyme p38 kinase is known for its role in inflammation and its inhibition is expected to stabilize atherosclerotic plaques and reduce plaque rupture thereby preventing thrombosis.

Sanofi and Regeneron has recently received a priority review certificate for its lead drug Praluent (alirocumab) an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). So far, ten Phase 3 clinical trials, including ODYSSEY OUTCOMES, will include over patients.

The next 5 years are expected to witness the launch of the key drugs Losmapimod (GSK), Praluent (Sanofi & Regeneron), Anacetrapib (Merck & Co.), Evacetrapib (Eli Lilly and Co.), and Evolocumab (Amgen), which will boost market share for branded drugs to approximately %.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen
  • Bayer
  • Bristol Myers Squibb
  • Eli Lilly and Co.
  • GlaxoSmithKline
  • Merck & Co.
  • MORE
1. Executive Summary
  • Executive Summary - Key Findings
  • Key Trends
  • Companies to Watch
2. Methodology and Scope

3. Market Overview
  • Market Overview - Introduction
  • Market Overview - Epidemiology
4. Physicians Treatment Guidelines
  • Market Size
  • Market Size - Segmentation
  • Market Forecast
  • Market Segmentation
5. Competitive Landscape - ACS Therapeutics (Marketed and Pipeline Products)
  • Competitive Landscape Overview
  • Competitive Landscape - Marketed and Pipeline Products
  • Marketed Products - Anti-platelet Therapy
  • Pipeline Products - Anti-platelet Therapy
  • Marketed Products - Anti-thrombin Therapy
  • Pipeline Products - Anti-thrombin Therapy
  • Marketed Products - Anti-hypertensives & Cholesterol Lowering Drugs
  • Pipeline Products - Anti-hypertensives & Cholesterol Lowering Drugs
  • Pipeline Products - Others
  • Product Launch Timeline
  • Patent Expirations
6. Pivotal Phase 3 Trials
  • ACS Therapeutics - Major Ongoing/Recently Completed Clinical Trials
  • Summary of Key Products to Watch
7. Product Dashboard (Key Marketed and Phase 3 Products)
  • Product Dashboard: Plavix (clopidogrel) - Bristol-Myers Squibb
  • Product Dashboard: Brilinta (ticagrelor) - The Medicines Company
  • Product Dashboard: Angiomax - The Medicines Company
  • Product Dashboard: Zocor (simvastatin) - Merck
  • Product Dashboard: Xarelto (rivaroxaban) - Bayer
  • Product Dashboard: Alirocumab (RGN727) - Sanofi & Regeneron
  • Product Dashboard: Evolocumab (Repatha) - Amgen
  • Product Dashboard: Evacetrapib - Eli Lilly & Company
  • Product Dashboard: Losmapimod - GSK
8. Conclusion
  • Legal Disclaimer
9. Appendix
  • Decision Support Database
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- Amgen
- Bayer
- Bristol Myers Squibb
- Eli Lilly and Co.
- GlaxoSmithKline
- Merck & Co.
- Regeneron
- Sanofi
- The Medicines Company

Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/3244520
Adroll
adroll